Severine Vermeire (S Vermeire, Séverine Vermeire)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 94

Top Topics

Ulcerative Colitis

Top Venues

Journal of Crohn's & colitis

Alimentary pharmacology & therapeutics

Inflammatory bowel diseases

United European gastroenterology journal

This page only lists publications with an associated author ORCID identifier.

Publications

Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy 14 (3) (2024)
Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Corey Allan Siegel, Victoria Rai, An Outtier, Severine Vermeire, Cindy C W Law, Bruce E Sands, Asim Abdulhamid, Richard Gearry, Josh McGuire, James O Lindsay, Remo Panaccione, Hagai Schweistein, Iris Dotan, Luca Scarallo, Anne M Griffiths, Marla C Dubinsky, null null
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials. Journal of Crohn's & colitis (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply. Alimentary pharmacology & therapeutics 59 (5) (2024)
Andres J Yarur, Michael V Chiorean, Julian Panes, Vipul Jairath, Jinkun Zhang, Christopher J Rabbat, William J Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. Journal of Crohn's & colitis 18 (6) (2024)
Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy 14 (3) (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy 14 (3) (2024)
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panes, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R A M D'Haens, Martina Goetsch, Karolina Wosik, Michael Keating, Krisztina Lazin, Joseph Wu, Irene Modesto, Aoibhinn McDonnell, Lauren Bartolome, Severine Vermeire
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn's & colitis 18 (8) (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy 14 (3) (2024)
Sara Deleu, Inge Jacobs, Jorge F Vazquez Castellanos, Sare Verstockt, Bruna Trindade de Carvalho, Ana Subotić, Bram Verstockt, Kaline Arnauts, Lowie Deprez, Eva Vissers, Matthias Lenfant, Greet Vandermeulen, Gert De Hertogh, Kristin Verbeke, Gianluca Matteoli, Geert R B Huys, Johan M Thevelein, Jeroen Raes, Severine Vermeire
Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis. Nutrients 16 (16) (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply. Alimentary pharmacology & therapeutics 59 (5) (2024)
Sara Deleu, Inge Jacobs, Jorge F Vazquez Castellanos, Sare Verstockt, Bruna Trindade de Carvalho, Ana Subotić, Bram Verstockt, Kaline Arnauts, Lowie Deprez, Eva Vissers, Matthias Lenfant, Greet Vandermeulen, Gert De Hertogh, Kristin Verbeke, Gianluca Matteoli, Geert R B Huys, Johan M Thevelein, Jeroen Raes, Severine Vermeire
Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis. Nutrients 16 (16) (2024)
Dahham Alsoud, Bram Verstockt, Severine Vermeire
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics. Inflammatory bowel diseases (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy (2024)
Nassim Hammoudi, David Sachar, Geert D'Haens, Walter Reinisch, Paulo Gustavo Kotze, Severine Vermeire, Jürgen Schölmerich, Michael A Kamm, Anne M Griffiths, Julian Panes, Subrata Ghosh, Corey Allan Siegel, Willem Bemelman, Colm O'Morain, Flavio Steinwurz, Phillip Fleshner, Gerassimos J Mantzaris, Bruce Sands, Maria T Abreu, Iris Dotan, Dan Turner, Axel Dignass, Matthieu Allez
Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus Conference. Journal of Crohn's & colitis 18 (6) (2024)
Gabriele Dragoni, Bo-Jun Ke, Lucia Picariello, Saeed Abdurahiman, Elisabetta Ceni, Francesca Biscu, Tommaso Mello, Simone Polvani, Tommaso Innocenti, Valérie Spalart, Stefano Milani, Andre D'Hoore, Gabriele Bislenghi, Stefano Scaringi, Bram Verstockt, Gert De Hertogh, Kimberly Martinod, Andrea Galli, Gianluca Matteoli, Severine Vermeire
The Impact of PAD4-dependent Neutrophil Extracellular Trap Formation on the Early Development of Intestinal Fibrosis in Crohn's Disease. Journal of Crohn's & colitis (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Dahham Alsoud, Bram Verstockt, Severine Vermeire
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics. Inflammatory bowel diseases 30 (5) (2024)
Andres J Yarur, Michael V Chiorean, Julian Panes, Vipul Jairath, Jinkun Zhang, Christopher J Rabbat, William J Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. Journal of Crohn's & colitis 18 (6) (2024)
Nassim Hammoudi, David Sachar, Geert D'Haens, Walter Reinisch, Paulo Gustavo Kotze, Severine Vermeire, Jürgen Schölmerich, Michael A Kamm, Anne M Griffiths, Julian Panes, Subrata Ghosh, Corey Allan Siegel, Willem Bemelman, Colm O'Morain, Flavio Steinwurz, Phillip Fleshner, Gerassimos J Mantzaris, Bruce Sands, Maria T Abreu, Iris Dotan, Dan Turner, Axel Dignass, Matthieu Allez
Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus Conference. Journal of Crohn's & colitis 18 (6) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Andres J Yarur, Michael V Chiorean, Julian Panes, Vipul Jairath, Jinkun Zhang, Christopher J Rabbat, William J Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. Journal of Crohn's & colitis 18 (6) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal (2024)
Tom M Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Severine Vermeire
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State. Dermatology and therapy 14 (3) (2024)
Anouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, Bram Verstockt, João Sabino, Severine Vermeire, Livia Guadagnoli, Ilse Van Diest, Marc Ferrante
Disease Acceptance, but not Perceived Control, is Uniquely Associated with Inflammatory Bowel Disease-related Disability. Journal of Crohn's & colitis 18 (7) (2024)
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panes, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R A M D'Haens, Martina Goetsch, Karolina Wosik, Michael Keating, Krisztina Lazin, Joseph Wu, Irene Modesto, Aoibhinn McDonnell, Lauren Bartolome, Severine Vermeire
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn's & colitis 18 (8) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring (2024)
Francisco Javier García-Alonso, Stefan Schreiber, Corey A Siegel, Fernando Magro, Anna Jus, Chiara Whichello, Christine Michaels-Igbokwe, Sebastian Heidenreich, Alessandra Oortwijn, Severine Vermeire
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study. Inflammatory bowel diseases (2024)
Andres J Yarur, Michael V Chiorean, Julian Panes, Vipul Jairath, Jinkun Zhang, Christopher J Rabbat, William J Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. Journal of Crohn's & colitis 18 (6) (2024)
Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R B Huys, Johan M Thevelein, Jeroen Raes, Severine Vermeire
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis. International journal of molecular sciences 24 (1) (2023)
Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca G Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H Iqbal, Sudarshan Paramsothy, Maurizio Sanguinetti, Silvio Danese, Herbert Tilg, Fabio Cominelli, Theresa T Pizarro, Alessandro Armuzzi, Giovanni Cammarota, Antonio Gasbarrini, Severine Vermeire, Franco Scaldaferri
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut (2023)
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Severine Vermeire, Christian Maaser, Silvio Danese, Margaux Faes, Paul Van Hoek, Jeremy Hsieh, Ulrik Moerch, Yan Zhou, Angela de Haas, Christine Rudolph, Alessandra Oortwijn, Edward V Loftus
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. Alimentary pharmacology & therapeutics (2023)
Bram Verstockt, Maaike Vancamelbeke, Severine Vermeire
Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease. Gut (2023)
Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R B Huys, Johan M Thevelein, Jeroen Raes, Severine Vermeire
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis. International journal of molecular sciences 24 (1) (2023)
Tom M Hillary, Michèle Grymonprez, Emma Vanhooren, Canan Güvenç, Marjan Garmyn, Severine Vermeire
Venous Thromboembolism in psoriasis patients: a retrospective monocentric chart review on an overlooked comorbidity. Clinical and experimental dermatology (2023)
Silvio Danese, Remo Panaccione, Maria T Abreu, David T Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T Osterman, Hsiuanlin Wu, James B Canavan, Ann Katrin Petersen, Jean Frederic Colombel, Miguel Regueiro
Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. Journal of Crohn's & colitis (2023)
Pieter Sinonquel, Alessandro Schilirò, Bram Verstockt, Severine Vermeire, Raf Bisschops
Evaluating the potential of artificial intelligence in ulcerative colitis. Expert review of gastroenterology & hepatology (2023)
Nassim Hammoudi, David Sachar, Geert D'Haens, Walter Reinisch, Paulo Gustavo Kotze, Severine Vermeire, Jürgen Schölmerich, Michael A Kamm, Anne M Griffiths, Julian Panes, Subrata Ghosh, Corey Allan Siegel, Willem Bemelman, Colm O'Morain, Flavio Steinwurz, Phillip Fleshner, Gerassimos J Mantzaris, Bruce Sands, Maria T Abreu, Iris Dotan, Dan Turner, Axel Dignass, Matthieu Allez, null null
Outcomes and endpoints of postoperative recurrence in Crohn's Disease: systematic review and consensus conference. Journal of Crohn's & colitis (2023)
Pieter Sinonquel, Alessandro Schilirò, Bram Verstockt, Severine Vermeire, Raf Bisschops
Evaluating the potential of artificial intelligence in ulcerative colitis. Expert review of gastroenterology & hepatology 17 (2) (2023)
Pieter Sinonquel, Alessandro Schilirò, Bram Verstockt, Severine Vermeire, Raf Bisschops
Evaluating the potential of artificial intelligence in ulcerative colitis. Expert review of gastroenterology & hepatology 17 (2) (2023)
Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel U Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Silvio Danese
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST. Alimentary pharmacology & therapeutics (2023)
Pieter Sinonquel, Alessandro Schilirò, Bram Verstockt, Severine Vermeire, Raf Bisschops
Evaluating the potential of artificial intelligence in ulcerative colitis. Expert review of gastroenterology & hepatology (2023)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis. Alimentary pharmacology & therapeutics (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Julian Panes, Severine Vermeire, Geert R D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Daniel R Gaya, Laurent Peyrin Biroulet, Axel U Dignass, null null
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial. United European gastroenterology journal (2023)
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, Rebecca A Mosig, Brian G Feagan, Jean-Frederic Colombel, Britta Siegmund, Florian Rieder, Stefan Schreiber, Andres Yarur, Remo Panaccione, Marla Dubinsky, Simon Lichtiger, Fabio Cataldi, Silvio Danese
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's & colitis (2023)
Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R B Huys, Johan M Thevelein, Jeroen Raes, Severine Vermeire
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis. International journal of molecular sciences 24 (1) (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Gabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, Albert M Wolthuis, Marc Ferrante, Gert de Hertogh, Severine Vermeire, André D'Hoore
Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study. Inflammatory bowel diseases (2023)
Paulo Gustavo Kotze, Severine Vermeire
Upgrading therapeutic ambitions and treatment outcomes. Nature reviews. Gastroenterology & hepatology (2023)
Marla C Dubinsky, David B Clemow, Theresa Hunter Gibble, Xingyuan Li, Severine Vermeire, Tadakazu Hisamatsu, Simon P L Travis
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission. Crohn's & colitis 360 5 (1) (2022)
Kaline Arnauts, Padhmanand Sudhakar, Sare Verstockt, Cynthia Lapierre, Selina Potche, Clara Caenepeel, Bram Verstockt, Jeroen Raes, Severine Vermeire, João Sabino, Catherine M Verfaillie, Marc Ferrante
Microbiota, not host origin drives ex vivo intestinal epithelial responses. Gut microbes 14 (1) (2022)
Padhmanand Sudhakar, Dahham Alsoud, Judith Wellens, Sare Verstockt, Kaline Arnauts, Bram Verstockt, Severine Vermeire
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn's & colitis 16 (8) (2022)
Dotan Yogev, Bram Verstockt, Axel Dignass, Gili Focht, Ohad Atia, Iris Dotan, Severine Vermeire, Dan Turner
The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease. Inflammatory bowel diseases (2022)
Dahham Alsoud, Gert De Hertogh, Griet Compernolle, Sophie Tops, João Sabino, Marc Ferrante, Debby Thomas, Severine Vermeire, Bram Verstockt
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. Journal of Crohn's & colitis 16 (10) (2022)
Johanne Brooks-Warburton, Dezső Módos, Padhmanand Sudhakar, Matthew Madgwick, John P Thomas, Balazs Bohar, David Fazekas, Azedine Zoufir, Orsolya Kapuy, Mate Szalay-Beko, Bram Verstockt, Lindsay J Hall, Alastair J M Watson, Mark Tremelling, Miles Parkes, Severine Vermeire, Andreas Bender, Simon R Carding, Tamas Korcsmaros
A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nature communications 13 (1) (2022)
Lucas Wauters, Raul Y Tito, Matthias Ceulemans, An Outtier, Leen Rymenans, Chloë Verspecht, João Sabino, Marc Ferrante, Severine Vermeire, Tim Vanuytsel, Jeroen Raes
Microbiome variance of the small bowel in Crohn's disease. Gut 72 (8) (2022)
Wannee Kantasiripitak, Marc Ferrante, Sebastian Georg Wicha, Alexander Kensert, Zhigang Wang, João Sabino, Severine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Huiwen Che, Tatjana Jatsenko, Lore Lannoo, Kate Stanley, Luc Dehaspe, Leen Vancoillie, Nathalie Brison, Ilse Parijs, Kris Van Den Bogaert, Koenraad Devriendt, Sabien Severi, Veerle Ide, Severine Vermeire, Bram Verstockt, Kristel Van Calsteren, Joris Robert Vermeesch
Machine learning-based detection of immune-mediated diseases from genome-wide cell-free DNA sequencing datasets. NPJ genomic medicine 7 (1) (2022)
Marla C Dubinsky, David B Clemow, Theresa Hunter Gibble, Xingyuan Li, Severine Vermeire, Tadakazu Hisamatsu, Simon P L Travis
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission. Crohn's & colitis 360 5 (1) (2022)
Gary R Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T Judd, Thomas Jones, Edward V Loftus
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflammatory bowel diseases (2022)
Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, Marc Ferrante, João Sabino, Severine Vermeire
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut (2022)
Walter Reinisch, Adrian Serone, Xavier Hébuterne, Tanja Kühbacher, Maria Kłopocka, Xavier Roblin, Jens Brodbeck, Kim Etchevers, René Galien, Ethan Grant, Chantal Tasset, Oh Kyu Yoon, Shiva Zaboli, Severine Vermeire
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. Tissue barriers (2022)
Tom M Hillary, Jolien Clijmans, Severine Vermeire, Jo Lambert, Marjan Garmyn, Maya Imbrechts, Thomas Vanassche
Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis. Annals of medicine 53 (1) (2021)
Annick Moens, Bram Verstockt, Dahham Alsoud, João Sabino, Marc Ferrante, Severine Vermeire
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflammatory bowel diseases (2021)
Judith Wellens, João Sabino, Severine Vermeire
PPIs and anti-TNF in patients with IBD: a forbidden combination? Gut 70 (12) (2021)
C Jorissen, Bram Verstockt, N Schils, João Sabino, Marc Ferrante, Severine Vermeire
Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scandinavian journal of gastroenterology 56 (11) (2021)
Brecht Creyns, Jonathan Cremer, Gert De Hertogh, Louis Boon, Marc Ferrante, Severine Vermeire, Gert Van Assche, Jan L Ceuppens, Christine Breynaert
Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells. Immunity, inflammation and disease 8 (3) (2020)
Evelyne Dubois, Annick Moens, Rob Geelen, João Sabino, Marc Ferrante, Severine Vermeire
Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European gastroenterology journal 8 (8) (2020)
Edward V Loftus, Brian G Feagan, Remo Panaccione, Jean Frederic Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert R A M D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Severine Vermeire
Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (8) (2020)
Erwin Dreesen, Sophie Berends, David Laharie, Geert D'Haens, Severine Vermeire, Ann Gils, Ron Mathôt
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. British journal of clinical pharmacology 87 (1) (2020)
Silvio Danese, Kavitha Subramaniam, Jan Van Zyl, Shashi Adsul, Dirk Lindner, Jeannine Roth, Severine Vermeire
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Alimentary pharmacology & therapeutics 53 (2) (2020)
Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 17 (6) (2020)
Karen van Hoeve, Severine Vermeire
Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatric drugs 22 (5) (2020)
Sofie Coenen, Egon Nijns, Ellen Weyts, Patricia Geens, Bart Van den Bosch, Severine Vermeire, Marc Ferrante, Kris Vanhaecht, Gert Van Assche
Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. Scandinavian journal of gastroenterology 55 (3) (2020)
Sare Verstockt, Bram Verstockt, Severine Vermeire
Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert opinion on therapeutic targets 23 (11) (2019)
Sara Vieira-Silva, João Sabino, Mireia Valles-Colomer, Gwen Falony, Gunter Kathagen, Clara Caenepeel, Isabelle Cleynen, Schalk van der Merwe, Severine Vermeire, Jeroen Raes
Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nature microbiology 4 (11) (2019)
Sofie Coenen, Ellen Weyts, Patricia Geens, Severine Vermeire, Marc Ferrante, Kris Vanhaecht, Gert Van Assche
Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. Scandinavian journal of gastroenterology 54 (5) (2019)
Gabriele Bislenghi, A Wolthuis, G Van Assche, Severine Vermeire, M Ferrante, A D'Hoore
Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. Expert opinion on biological therapy 19 (7) (2019)
Gwen Falony, Doris Vandeputte, Clara Caenepeel, Sara Vieira-Silva, Tanine Daryoush, Severine Vermeire, Jeroen Raes
The human microbiome in health and disease: hype or hope. Acta clinica Belgica 74 (2) (2019)
Brecht Creyns, Jonathan Cremer, Tomoaki Hoshino, Karel Geboes, Gert de Hertogh, Marc Ferrante, Severine Vermeire, Jan L Ceuppens, Gert Van Assche, Christine Breynaert
Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13. Scientific reports 9 (1) (2019)
Bram Verstockt, Gitte Moors, Sumin Bian, Thomas Van Stappen, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Alimentary pharmacology & therapeutics 48 (7) (2018)
Bram Verstockt, Severine Vermeire, Gert Van Assche, Marc Ferrante
When IBD is not IBD. Scandinavian journal of gastroenterology 53 (9) (2018)
Maaike Vancamelbeke, Severine Vermeire
The intestinal barrier: a fundamental role in health and disease. Expert review of gastroenterology & hepatology 11 (9) (2017)
Magali de Bruyn, Severine Vermeire
NOD2 and bacterial recognition as therapeutic targets for Crohn's disease. Expert opinion on therapeutic targets 21 (12) (2017)
Thomas Billiet, Isabelle Cleynen, Vera Ballet, Karolien Claes, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche, Ann Gils, Severine Vermeire
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. Scandinavian journal of gastroenterology 52 (10) (2017)
Karen van Hoeve, Ilse Hoffman, Severine Vermeire
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert opinion on drug safety 17 (2) (2017)
Bram Verstockt, Barbara Deleenheer, Gert Van Assche, Severine Vermeire, Marc Ferrante
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert opinion on drug safety 16 (7) (2017)